Prices are updated after-hours

Professional, Scientific, and Technical Services 2022 - 06 - 13

VectivBio Holding AG

VECT | $16.85 0.12% 130K

(0.0% 1d) (0.0% 1m) (87.2% 1y) (0.0% 2d) (0.2% 3d) (0.0% 7d) (-48.24% volume)
Earnings Calendar:
Market Cap: $ 1,057,156,615
https://vectivbio.com
Sec Filling | Patents | 32 employees

VectivBio is a global, clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions with high unmet medical need. The company is committed to pursuing product candidates with a clear mechanism of action and the potential to meaningfully transform and improve the lives of patients and their families. VectivBio’s product candidate, apraglutide, is a next-generation GLP-2 analog being developed as a differentiated therapeutic for a range of rare gastrointestinal (GI) diseases. Apraglutide is currently being evaluated in a global phase 3 clinical trial as a once-weekly treatment for short bowel syndrome with intestinal failure (SBS-IF).

msa gastrointestinal treatment

add to watch list Paper trade email alert is off

Bright Mountain Media, Inc.

BMTM | $0.0541 3021.1% 29K

Professional, Scientific, and T...

(0.0% 1d) (-32.5% 1m) (-39.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (14316.0% volume)
Earnings Calendar:
Market Cap: $ 9,336,958

Sec Filling | Patents | 55 employees

we are the fully integrated media company for our nation’s heroes. by combining content creation, ad delivery, and ecommerce into one company, we provide a superior experience for our audience and extraordinary results for advertisers. bright mountain ad network connects advertisers with the best publishers with military and public safety audiences. we optimize the revenue and user experience for digital content creators. bright mountain ecommerce markets brands that represent the fearless side of being a hero. brands like black helmet and certified wolf hunter provide apparel and lifestyle gear that can be worn in brotherhood with pride. bright mountain publishing division attracts over 4 million unique visitors each month and has over 2.5 million social media fans with leading edge content, compelling news coverage, and editorial analysis. our brands include: blackhelmetapparel.com bootcamp4me.com thebravestonline.com thebright.com brightmountainads.com brightwatches.com coastguardne

ycombinator

add to watch list Paper trade email alert is off

Molecular Partners AG - ADR

MOLN | $3.67 -3.42% -3.54% 320

Professional, Scientific, and T...

(0.0% 1d) (1.0% 1m) (-37.2% 1y) (0.0% 2d) (0.0% 3d) (-1.0% 7d) (-51.97% volume)
Earnings Calendar:
Market Cap: $ 133,473,867
https://www.molecularpartners.com/
Sec Filling | Patents | 124 employees

(CH) brave bison is a social video company. we work with brands, creators and platforms to create, distribute and monetise video that’s fit for a digital world. we help to define brands’ needs in the content space to achieve actual business goals, helping them to crystallise why they should create social video in the first place and who to make it for. therefore how to execute it and how to distribute it in order to make a return on investment. we originate excellent branded content ideas that work in a digital world. culturally relevant ideas grounded in human insight and informed by data. real stories about real people; because we know that’s what garners engagement. content fit for purpose on ever-evolving digital platforms. there’s little point creating great video if no one’s watching it. so we distribute social video content; measuring, learning and acting on its performance. we work with brands to manage and distribute on owned channels to ensure that the best social video practice i

add to watch list Paper trade email alert is off

Lyell Immunopharma Inc

LYEL | $2.34 -1.68% -1.71% 910K

Professional, Scientific, and T...

(0.0% 1d) (19.6% 1m) (-2.9% 1y) (0.0% 2d) (-1.2% 3d) (-20.9% 7d) (-22.75% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 594,585,368
https://lyell.com
Sec Filling | Patents | 189 employees

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.

genetic t-cell renewable

add to watch list Paper trade email alert is off

Nukkleus Inc.

NUKK | $0.8758 -6.24% 140K

Professional, Scientific, and T...

(0.0% 1d) (6.7% 1m) (439900.0% 1y) (0.0% 2d) (5.4% 3d) (3.5% 7d) (-11.26% volume)
Earnings Calendar:
Market Cap: $ 0
https://www.nukk.com/
Sec Filling | Patents | 1 employees

(US) nukkleus, inc. (otc: nukk) is a fintech group that acquires, builds and scales blockchain and digital financial services businesses. the portfolio serves b2b and institutional clients with the aim of disrupting the banking & investment industry for the better.

add to watch list Paper trade email alert is off

OMNIQ Corp

OMQS | News | $0.529 -14.36% -16.77% 500K

Professional, Scientific, and T...

(0.0% 1d) (4.9% 1m) (-85.9% 1y) (0.0% 2d) (11.5% 3d) (19.2% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 5,655,122
https://www.omniq.com
Sec Filling | Patents | 61 employees

OMNIQ Corp. provides computerized and machine vision image processing solutions that use patented and proprietary AI technology to deliver data collection, real-time surveillance and monitoring for supply chain management, homeland security, public safety, traffic & parking management and access control applications. The technology and services provided by the Company help clients move people, assets and data safely and securely through airports, warehouses, schools, national borders, and many other applications and environments. OMNIQ’s customers include government agencies and leading Fortune 500 companies from several sectors, including manufacturing, retail, distribution, food and beverage, transportation and logistics, healthcare, and oil, gas, and chemicals. Since 2014, annual revenues have grown to more than $50 million from clients in the USA and abroad. The Company currently addresses several billion-dollar markets, including the Global Safe City market, forecast to grow to $29 billion by 2022, and the Ticketless Safe Parking market, forecast to grow to $5.2 billion by 2023.

security

add to watch list Paper trade email alert is off

Quoin Pharmaceuticals Ltd - ADR

QNRX | $0.725 -1.11% -1.12% 9.9K

Professional, Scientific, and T...

(0.0% 1d) (-18.0% 1m) (-98.9% 1y) (0.0% 2d) (1.4% 3d) (-1.5% 7d) (6.7% volume)
Earnings Calendar:
Market Cap: $ 2,672,328
https://cellect.co
Sec Filling | Patents | 2020 employees

(IL) Cellect Biotechnology has developed a breakthrough technology, for the selection of stem cells from any given tissue, that aims to improve a variety of stem cell-based therapies.

ceiling t-cell

add to watch list Paper trade email alert is off

Compass Therapeutics Inc

CMPX | $1.5 -1.96% -2.0% 240K

Professional, Scientific, and T...

(0.0% 1d) (-26.6% 1m) (-48.4% 1y) (0.0% 2d) (0.0% 3d) (-3.1% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 206,383,757

Sec Filling | Patents | 26 employees

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

add to watch list Paper trade email alert is off

Day One Biopharmaceuticals Inc

DAWN 4 | $15.76 6.13% 5.77% 1.9M

Professional, Scientific, and T...

(0.0% 1d) (5.9% 1m) (15.3% 1y) (0.0% 2d) (0.0% 3d) (6.1% 7d) (22.59% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,377,064,089
https://dayonebio.com
Sec Filling | Patents | 20 employees

(US) Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Its name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. The company aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One. Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial (FIREFLY-1) in pediatric, adolescent and young adult patients with recurrent or progressive low-grade glioma (pLGG). The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2 (MEK). Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.

treatment diagnostics cancer

add to watch list Paper trade email alert is off

Instil Bio Inc

TIL | $10.41 -1.65% -1.68% 7.5K

Professional, Scientific, and T...

(0.0% 1d) (-12.6% 1m) (1508.2% 1y) (0.0% 2d) (2.5% 3d) (-2.8% 7d) (-6.65% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 67,705,734
https://instilbio.com
Sec Filling | Patents | 412 employees

(US) Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.

cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

BioRestorative Therapies, Inc.

BRTX | $1.435 3.24% 3.14% 250K

Professional, Scientific, and T...

(0.0% 1d) (-6.4% 1m) (-64.9% 1y) (0.0% 2d) (0.0% 3d) (-2.2% 7d) (42767.95% volume)
Earnings Calendar:
Market Cap: $ 9,714,834
http://www.biorestorative.com/
Sec Filling | Patents | 5 employees

(US) biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas

injection t-cell

add to watch list Paper trade email alert is off

Verve Therapeutics Inc

VERV | $6.66 -1.19% -1.2% 1.2M

Professional, Scientific, and T...

(0.0% 1d) (-48.2% 1m) (-58.2% 1y) (0.0% 2d) (-5.6% 3d) (-11.3% 7d) (67.18% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 556,904,398
https://www.vervetx.com
Sec Filling | Patents | 63 employees

Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

genetic cardiovascular

add to watch list Paper trade email alert is off

BriaCell Therapeutics Corp.

BCTX | $2.19 -5.6% -5.94% 140K

Professional, Scientific, and T...

(0.0% 1d) (1.8% 1m) (-61.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off